Hohl P, Zollinger-Iten J, von Graevenitz A
Preclinical Research, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Antimicrob Agents Chemother. 1992 Dec;36(12):2835-8. doi: 10.1128/AAC.36.12.2835.
The in vitro activities of Ro 40-6890, the active metabolite of a novel orally absorbable cephalosporin ester, Ro 41-3399, against 164 nonfastidious aerobic gram-negative rods of predominantly intestinal origin from patients with diarrhea were evaluated by the agar dilution method recommended by the National Committee for Clinical Laboratory Standards. Ro 40-6890 was inhibitory (MIC for 90% of isolates [MIC90], 0.12 micrograms/ml) against the majority of intestinal members of the families Enterobacteriaceae and Vibrionaceae (Vibrio spp., Aeromonas spp., and Plesiomonas shigelloides). The potency of Ro 40-6890 was very similar to that of cefotaxime (MIC90, 0.12 micrograms/ml) and distinctly higher than those of cefadroxil (MIC90, > or = 128 micrograms/ml) and amoxicillin-clavulanic acid (MIC90, 32 micrograms/ml-2 micrograms/ml).
采用美国国家临床实验室标准委员会推荐的琼脂稀释法，对新型口服吸收性头孢菌素酯Ro 41-3399的活性代谢产物Ro 40-6890针对腹泻患者来源的164株主要源自肠道的非苛养需氧革兰氏阴性杆菌的体外活性进行了评估。Ro 40-6890对肠杆菌科和弧菌科（弧菌属、气单胞菌属和类志贺邻单胞菌）的大多数肠道菌具有抑制作用（90%菌株的最低抑菌浓度[MIC90]为0.12微克/毫升）。Ro 40-6890的效力与头孢噻肟（MIC90为0.12微克/毫升）非常相似，明显高于头孢羟氨苄（MIC90≥128微克/毫升）和阿莫西林-克拉维酸（MIC90为32微克/毫升至2微克/毫升）。
